CD1a CARTs fully control the progression of coT-ALL cells in a mouse xenograft setting. (A) Scheme of the xenograft model. NSG mice (n = 6/group) were IV injected with 3 × 106 Luc/GFP–expressing Jurkat cells followed 3 days after by a single IV injection of 5 × 106 MOCK or CD1a CARTs. Tumor burden was monitored every 4 to 6 days according to BLI using IVIS imaging. When MOCK-treated animals were fully leukemic, one-half of the CD1a CART-treated animals were euthanized and analyzed by using FACS (BM, PB, and spleen) for leukemic burden and CART persistence. The remaining animals were rechallenged 6 weeks later with 1.5 × 106 Luc-Jurkat cells and were followed up as before. (B) IVIS imaging of tumor burden monitored by BLI at the indicated time points. (C) Total radiance quantification at the indicated time points. †Euthanization. (D) Circulating Jurkat cells in PB 17 days after CARTs infusion. (E) T-cell persistence in PB at day 17, and spleen and BM at euthanization. Data are shown as mean ± SD (n = 6 mice/group). *P < .05, **P < .01, ***P < .001.